DMAAU Drugs Made In America Acquisition Corp.: institutional ownership and insider trading
4 funds reported holding $3.64M of Drugs Made In America Acquisition Corp. in their latest 13F filings; in Q2 2026 funds net bought $95, with 0 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
DMAAU revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income $1.73M
- Quarter ended Mar 31, 2026: revenue n/a, net income $1.97M
- Quarter ended Dec 31, 2025: revenue n/a, net income $213K
- Quarter ended Sep 30, 2025: revenue n/a, net income $2.18M
Largest institutional holders of DMAAU
- KRYGER CAPITAL Ltd — $3.04M
- CLEAR STREET LLC — $474K
- Clear Street Group Inc. — $106K
- UBS Group AG (UBS) — $16.2K
Recent DMAAU insider trades
- Feb 18, 2025: Stockwell Lynn bought 30,000 shares ($0)
- Feb 18, 2025: Drugs Made In America Acquisition LLC bought 30,000 shares ($0)
- Jan 29, 2025: Drugs Made In America Acquisition LLC sold 5,698,363 shares ($0)
- Jan 29, 2025: Drugs Made In America Acquisition LLC bought 400,000 shares ($0)
5%+ owners
- Drugs Made In America Acquisition LLC: 12.5% (Schedule 13D, filed Mar 3, 2025)
- KARPUS MANAGEMENT, INC.: 10.3% (Schedule 13G/A, filed Aug 14, 2026)
- Mizuho Financial Group, Inc.: 8.5% (Schedule 13G/A, filed Aug 13, 2026)
- Polar Asset Management Partners Inc.: 5.7% (Schedule 13G, filed May 15, 2025)
- Feis Equities LLC: 5.1% (Schedule 13G, filed Jun 26, 2026)